209 related articles for article (PubMed ID: 37884388)
1. Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade.
Nelke C; Pawlitzki M; Kerkhoff R; Schroeter CB; Aktas O; Neuen-Jacob E; Polzin A; Meuth SG; Ruck T
Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37884388
[TBL] [Abstract][Full Text] [Related]
2. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R
Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
[TBL] [Abstract][Full Text] [Related]
6. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
[TBL] [Abstract][Full Text] [Related]
7. Novel uses of complement inhibitors in myasthenia gravis-Two case reports.
Zadeh S; Price H; Drews R; Bouffard MA; Young LH; Narayanaswami P
Muscle Nerve; 2024 Mar; 69(3):368-372. PubMed ID: 38205840
[TBL] [Abstract][Full Text] [Related]
8. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit.
Deharo F; Carvelli J; Cautela J; Garcia M; Sarles C; Maues de Paula A; Bourenne J; Gainnier M; Bichon A
J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233479
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors induced side effects of the peripheral nervous system.
Hundsberger T; Schreiner B; Roth P
Curr Opin Neurol; 2023 Oct; 36(5):427-431. PubMed ID: 37639489
[TBL] [Abstract][Full Text] [Related]
12. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition.
Puwanant A; Isfort M; Lacomis D; Živković SA
Neuromuscul Disord; 2019 Feb; 29(2):127-133. PubMed ID: 30638612
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.
Giovannini E; Bonasoni MP; D'Aleo M; Tamagnini I; Tudini M; Fais P; Pelotti S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446095
[TBL] [Abstract][Full Text] [Related]
14. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy.
Saygin D; Ghosh N; Reid P
J Clin Rheumatol; 2022 Oct; 28(7):367-373. PubMed ID: 35696731
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review.
Gao L; Li X; Guo Z; Tang L; Peng J; Liu B
Medicine (Baltimore); 2022 Dec; 101(49):e32240. PubMed ID: 36626474
[TBL] [Abstract][Full Text] [Related]
17. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
[TBL] [Abstract][Full Text] [Related]
18. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.
Cham J; Ng D; Nicholson L
J Med Case Rep; 2021 May; 15(1):278. PubMed ID: 34053457
[TBL] [Abstract][Full Text] [Related]
19. How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors.
Jordan B; Benesova K; Hassel JC; Wick W; Jordan K
ESMO Open; 2021 Dec; 6(6):100317. PubMed ID: 34839103
[TBL] [Abstract][Full Text] [Related]
20. A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event.
Lin X; Guan W; Li B; Deng H; Chen Y; Yang Y; Qiu G; Xie X; Zhou C
Immunopharmacol Immunotoxicol; 2023 Dec; 45(6):780-787. PubMed ID: 37339370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
